%0 Journal Article
%T Switching Tenofovir/Emtricitabine/Efavirenz (TDF/FTC/EFV) to TDF/FTC/Rilpivirine vs Continuing TDF/FTC/EFV in HIV-Infected Patients With Virological Suppression: A Randomized Controlled Trial
%A Sirichai Wiriyatanakorn
%A Somnuek Sungkanuparph
%J Archive of "Open Forum Infectious Diseases".
%D 2019
%R 10.1093/ofid/ofz297
%X A randomized controlled noninferiority trial was conducted in HIV-infected patients receiving tenofovir/emtricitabine/efavirenz (TDF/FTC/EFV) with virological suppression in a resource-limited setting. Switching to TDF/FTC/rilpivirine was noninferior to continuing TDF/FTC/EFV in terms of maintaining compete viral suppression at 24 weeks and provided better lipid profiles and fewer central nervous system adverse effects
%K efavirenz
%K rilpivirine
%K switching
%K antiretroviral therapy
%K randomized controlled trial
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6641787/